Virtualscopics and Ixico collaborated with Micron
Erik Jensen, vice president global business development and marketing of VirtualScopics, said "In 2014 we experienced a 25% increase in the number of awarded global Phase III trials over the previous year and we also received new study awards from 9 of the top 15 Pharma companies. We anticipate our momentum will continue in 2015. The collaboration agreement with Micron, together with our previously signed Alliance Framework Agreement with IXICO, will enable VirtualScopics to continue gaining presence with top Pharma companies and strengthen our global Phase III capabilities in the market place."
John Hall, vice president business development, IXICO, said "we are pleased to be collaborating with Micron. This expands the Alliance's reach and capabilities internationally and especially in Asia where it offers the opportunity to build on our existing client base in Japan, China and Korea."
Michael Tintiuc, Director of Foreign Affairs, Business Development, Micron, said "This signed collaboration agreement will allow Micron to expand its services outside of Japan to the markets of North America and Europe. We are excited to work together with VirtualScopics and IXICO and provide our clients a unique opportunity to conduct business from key global locations in the US, UK and Japan."
About VirtualScopics, Inc.
VirtualScopics, Inc. (NASDAQ:VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development. For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly-accepted services provided by other clinical trial imaging providers. Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, everyday clinical trial imaging services.
Комментарии